UNIGE document Scientific Article
previous document  unige:7389  next document
add to browser collection

A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia

Kollef, Marin
Sanchez Garcia, Miguel
Chastre, Jean
Fagon, J. Y.
Bonten, Marc
Hyzy, Robert
Fleming, T. R.
show hidden authors show all authors [1 - 16]
Published in American Journal of Respiratory and Critical Care Medicine. 2006, vol. 173, no. 1, p. 91-97
Abstract RATIONALE: Iseganan, an antimicrobial peptide, is active against aerobic and anaerobic gram-positive and gram-negative bacteria as well as fungi and yeasts. The drug has shown little resistance in vitro and to be safe and well tolerated in 800 patients with cancer treated for up to 6 wk. OBJECTIVES: To determine the efficacy of iseganan for the prevention of ventilator-associated pneumonia (VAP). METHODS: Mechanically ventilated patients in the United States and Europe were randomized to oral topical iseganan or placebo (1:1) and treated six times per day while intubated for up to 14 d. Patients were eligible if randomized within 24 h of intubation and estimated to survive and remain mechanically ventilated for 48 h or more. The primary efficacy endpoint of the study was VAP measured among survivors at Day 14. MEASUREMENTS AND MAIN RESULTS: A total of 709 patients were randomized and received at least one dose of study drug. The two groups were comparable at baseline except iseganan-treated patients were, on average, 3 yr older. The rate of VAP among survivors at Day 14 was 16% (45/282) in patients treated with iseganan and 20% (57/284) in those treated with placebo (p = 0.145). Mortality at Day 14 was 22.1% (80/362) in the iseganan group compared with 18.2% (63/347) in the placebo group (p = 0.206). No pattern of excess adverse events in the iseganan group compared with placebo was observed. CONCLUSIONS: Iseganan is not effective in improving outcome in patients on prolonged mechanical ventilation.
Keywords Administration, OralAdministration, TopicalAdultAgedAnti-Infective Agents/ administration & dosage/therapeutic useDouble-Blind MethodHumansMaleMiddle AgedPeptides/ administration & dosage/therapeutic usePneumonia/etiology/ prevention & controlRespiration, Artificial/ adverse effectsTreatment Outcome
PMID: 16192451
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://ajrccm.atsjournals.org/cgi/reprint/173/1/91.pdf
Research group Staphylocoques dorés résistants à la méthicilline et hygiène hospitalière (330)
(ISO format)
KOLLEF, Marin et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. In: American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, n° 1, p. 91-97. doi: 10.1164/rccm.200504-656OC https://archive-ouverte.unige.ch/unige:7389

360 hits

1 download


Deposited on : 2010-06-21

Export document
Format :
Citation style :